Article Details
Retrieved on: 2024-05-07 15:29:01
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article announces Hugo Fry's appointment as CEO of Topas Therapeutics, a Hamburg-based biotech firm focusing on immune tolerance therapies, which is relevant for stakeholders in biotech, including companies like Sanofi and Evotec.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here